AXL and acute myeloid leukemia: Small molecule selective inhibitors (Table 1), multitargeted inhibitors (Tables 1 and 2), antibody-drug conjugates (ADC) (Table 3) and anti-AXL-Fc fusion proteins (Table 3) have shown promising preclinical efficacy towards AML, attenuating leukemic cell proliferation, inducing apoptosis, and enhancing the efficacy of standard chemo- and immunotherapeutic agents.